Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02300311
Recruitment Status : Completed
First Posted : November 25, 2014
Results First Posted : September 13, 2016
Last Update Posted : September 13, 2016
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Tracking Information
First Submitted Date  ICMJE November 24, 2014
First Posted Date  ICMJE November 25, 2014
Results First Submitted Date  ICMJE May 24, 2016
Results First Posted Date  ICMJE September 13, 2016
Last Update Posted Date September 13, 2016
Study Start Date  ICMJE January 2015
Actual Primary Completion Date May 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 26, 2016)
Pain Intensity Difference (PID) From Pre-dose Baseline to 8h After the First Trial Medication Application (PID8h) [ Time Frame: Baseline and 8 hours after trial medication application ]
Pain intensity (PI) was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3, 4, 6 and 8 hours after trial medication application. The left side of each scale (0) is marked 'no pain' and the right side of the scale (10) is marked 'worst pain possible'. PID8h= Pain intensity (PI)8h - PI(baseline). Means reported are the adjusted means.
Original Primary Outcome Measures  ICMJE
 (submitted: November 24, 2014)
Pain intensity difference (PID) from pre-dose baseline 8h after 1st application using a 0-10 numerical rating scale (NRS) [ Time Frame: 8 hours ]
Change History Complete list of historical versions of study NCT02300311 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 26, 2016)
  • Pain Intensity Difference (PID) From Pre-dose Baseline to 4 Hours After the First Trial Medication Application (PID4h) [ Time Frame: Baseline and 4 hours after trial medication application ]
    Pain intensity was assessed on a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst pain possible) at pre-dose baseline and 0.5, 1, 2, 3 and 4 hours after trial medication application. The left side of each scale (0) is marked 'no pain' and the right side of the scale (10) is marked 'worst pain possible'. PID4h= PI(4h) - PI(baseline). Means reported are the adjusted means.
  • Difference of Average Pain Intensity (APID) From Pre-dose Baseline on the Last Individual Treatment Day [ Time Frame: Baseline and 1 to 4 days ]
    Difference of average pain intensity from pre-dose baseline on the last individual treatment day (The last individual treatment day was the last day on which the patient had recorded the study drug applications within the patient diary). Pain intensity was assessed by the patient using 0-10 numerical rating scale (NRS). Patients were given two 0-10 numerical rating scales (NRS) - to self-report of pain intensity at given time points for the period 0-8 hours post first dose and to self-report of average pain intensity they had at each treatment day. The left side of each scale (0) is marked 'no pain' and the right side of the scale (10) is marked 'worst pain possible'. APIDtime point = APItime point - PI baseline (time point is the last individual treatment day (either Day 1, 2, 3 or 4 after drug administration)). Means reported are the adjusted means.
  • Patient's Assessment of the Efficacy on the Last Individual Treatment Day [ Time Frame: 1 to 4 days ]
    Patients were asked to rate the effect of the study medication for relieving their low back pain using a 4-point verbal rating scale (1=Poor, 2= Fair, 3=Good, 4=Very Good).
Original Secondary Outcome Measures  ICMJE
 (submitted: November 24, 2014)
  • Pain intensity difference (PID) from pre-dose baseline 4h after 1st application using a 0-10 numerical rating scale (NRS) [ Time Frame: 4 hours ]
  • Difference of average pain intensity from pre-dose baseline on the last individual treatment day using a 0-10 numerical rating scale (NRS) [ Time Frame: up to 4 days ]
  • Patient's assessment of the efficacy on the last individual treatment day on a 4-point categorical self-reporting scale [ Time Frame: up to 4 days ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain
Official Title  ICMJE A Multinational, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Finalgon® Cream (1.08% Nicoboxil/ 0.17% Nonivamide) in the Treatment of Acute Low Back Pain
Brief Summary To evaluate efficacy of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide) versus placebo in patients with acute low back pain. To investigate the safety and tolerability of repeated use of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Low Back Pain
Intervention  ICMJE
  • Drug: nonivamide + nicoboxil (Finalgon cream)
    2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
  • Drug: placebo matching nonivamide + nicoboxil (Finalgon cream)
    2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
Study Arms  ICMJE
  • Experimental: nonivamide + nicoboxil (Finalgon cream)
    2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
    Intervention: Drug: nonivamide + nicoboxil (Finalgon cream)
  • Placebo Comparator: placebo
    2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
    Intervention: Drug: placebo matching nonivamide + nicoboxil (Finalgon cream)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 24, 2014)
138
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE May 2015
Actual Primary Completion Date May 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  1. Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines and local regulation prior to participation in the trial.
  2. Patients must agree to cooperate with all trial evaluations and perform all required tasks.
  3. Patients must have acute nonspecific low back pain, ICD-10 code: M54.5.
  4. Patients must have acute low back pain for more than 2 days and less than 21 days (= 3 weeks).
  5. Male or female more or equal 18 and less or equal 65 years of age at Visit 1(Baseline).
  6. Low back pain Pain intensity more or equal 5 on a 0-10 numerical rating scale (NRS).

Exclusion criteria:

  1. Patients with a significant disease other than acute nonspecific low back pain. A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial.
  2. Multilocular pain or panalgesia.
  3. History of more than 3 low back pain episodes in the last 6 months.
  4. Acute low back pain due to vertebral collapse or neoplastic, inflammatory (ankylosing spondylitis), traumatic, or infective origins.
  5. Abnormal findings in at least one of the following assessments: Achilles tendon reflex, patella reflex, heel walking, toe walking, cutaneous sensitivity of the legs (including gluteal region), paresis tests in supine position upon dorsiflexion, plantarflexion, hip flexion, knee extension.
  6. Neurogenic Bladder and/or rectum dysfunction.
  7. Any condition, disease or concomitant treatment that in the judgement of the investigator will affect the patient's ability to participate in the clinical trial or which will influence the trial methodology used.
  8. Negative experience in the past with heat treatment for muscle complaints (e. g. hot water bottle, heat pads, hyperemisation-inducing topical creams, ointments or patches).
  9. Patients with history of treatment of back pain with centrally acting drugs (e.g. opioids) and muscle relaxants within 6 months prior to enrolment.
  10. Surgery due to back pain or rehabilitation due to back pain in the last 12 months.
  11. Spinal injection back pain treatment within 6 months prior to enrolment.
  12. Intake of antidepressant/antipsychotic medication within 4 weeks prior to enrolment.
  13. Treatment of the recent low back pain period with oral analgesics for more than 4 consecutive days.
  14. Locally applied medication to the back within 24 hours prior to enrolment (topical treatments, injections).
  15. Non-pharmacological low back pain treatment (physiotherapy, heat treatment [e.g. hot water bottle, heat patch], or massages) within 12 hours prior to enrolment.
  16. Administration of other analgesics within 12 h prior to enrolment (exception: acetylsalicylic acid [ASS] up to 100 mg/daily for anti-platelet-aggregation therapy).
  17. Non-pharmacological low back pain treatment (physiotherapy, heat treatment [e.g. hot water bottle, heat patch], or massages) within 12 hours prior to enrolment.
  18. Participation in an investigational drug or device trial within 4 weeks prior to enrolment.
  19. History of treatment of back pain with centrally acting drugs (e.g. opioids) and muscle relaxants.
  20. Treatment of the recent low back pain period with oral analgesics for more than 4 consecutive days.
  21. Surgery due to back pain or rehabilitation due to back pain in the last 12 months.
  22. Spinal injection back pain treatment within 6 months prior to enrolment.
  23. Intake of antidepressant/antipsychotic medication within 4 weeks prior to enrolment.
  24. Known hypersensitivity to nicoboxil, nonivamide, or other ingredients of the cream.
  25. Known hypersensitivity to paracetamol.
  26. Skin lesions (e.g. rash, bruising, laceration) in the back region.
  27. Known history of central nervous system diseases with severe intellectual and memory disorders, psychiatric disorders.
  28. History of abuse of alcohol/drugs within six months prior to enrolment.
  29. Acute and relapsed chronic kidney diseases.
  30. Severe hepatocellular insufficiency.
  31. Pregnant or nursing women, including female patients with positive ß-HCG test at Visit 1.
  32. Female patients of child-bearing potential not using highly effective method of birth control.
  33. Patients who are currently participating in another trial or who have been participating in another trial within one month prior to Visit 1, and patients who have previously been randomised in this trial.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Russian Federation,   Ukraine
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02300311
Other Study ID Numbers  ICMJE 69.53
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
PRS Account Boehringer Ingelheim
Verification Date July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP